Review · Open Access ·

Treatment of coronary in-stent restenosis: a systematic review

Leos Pleva¹, Pavel Kukla¹, Ota Hlinomaz²,³
¹Department of Cardiovascular Diseases, University Hospital Ostrava, Czech Republic
²Department of Cardioangiology, St. Anne’s University Hospital and Faculty of Medicine, Masaryk University, Brno, CZ, Czech Republic
³International Clinical Research Center, St. Anne’s University Hospital, Brno, CZ, Czech Republic

Abstract

Coronary stent implantation has significantly improved percutaneous coronary intervention and enabled the management of early complications of plain balloon angioplasty. However, a new complication has accompanied these improvements: in-stent restenosis (ISR) arising from neointimal hyperplasia. ISR after coronary angioplasty is currently one of the main limitations of this method, leading to the recurrence of exertional angina pectoris or acute coronary syndromes. The clinical incidence of ISR after bare-metal stent (BMS) implantation is approximately 20%–35%. The use of drug-eluting stents (DES) has led to a further decrease in the occurrence of ISR to 5%–10%. Evidence resulting from controlled clinical studies suggests that DES and drug-eluting balloon catheters (DEB) provide the best clinical and angiographic results in the treatment of ISR. We undertook a systematic review of the pathophysiology, diagnostics and treatment options for BMS- and DES-ISR. We discuss recent randomised studies, comparing different DES or DEB used for BMS or DES-ISR treatment, as well as the use of new biovascular scaffolds and the topic of scaffold restenosis.

J Geriatr Cardiol 2018; 15: 173–184. doi:10.11909/j.issn.1671-5411.2018.02.007

Keywords: Drug-eluting balloon; Drug-eluting stent; In-stent restenosis

1 Introduction

Coronary stent implantation has significantly improved percutaneous coronary intervention (PCI) and enabled the management of early complications of plain balloon angioplasty (POBA). By preventing elastic recoil and constrictive remodeling, coronary stent implantation decreases the frequency of restenosis after PCI. However, a new complication has accompanied these improvements: in-stent restenosis (ISR) arising from neointimal hyperplasia. The clinical incidence of ISR after bare-metal stent (BMS) implantation is approximately 20%–35%. The use of drug-eluting stents (DES) has led to a further decrease in the occurrence of ISR to 5%–10%. Evidence resulting from controlled clinical studies suggests that DES and drug-eluting balloon catheters (DEB) provide the best clinical and angiographic results in the treatment of ISR.

Restenosis is defined as the repeated narrowing of the dilated segment of a coronary artery. Angiographic restenosis is defined as the ≥50% narrowing of the artery’s diameter during a subsequent coronary angiography. Restenosis resulting in the recurrence of clinical manifestations of ischemia is called “clinical restenosis”, which is usually associated with the necessity to repeat target lesion or vessel revascularisation (TLR/TVR). In-stent restenosis is a restenosis in an implanted coronary stent; if we evaluate not only the area of the stent, but the whole affected segment of the vessel, we refer to it as in-segment restenosis (+5 mm from the proximal and distal edges of the stent).

The generally used Mehran’s angiographic classification divides ISR into four types: I-focal; II-diffuse; III-proliferative and IV-occlusive (Table 1).

2 Drug-eluting stents restenosis

DES enable the local release of antiproliferative agents [paclitaxel or “limes” drug group (sirolimus, everolimus, zotarolimus, biolimus, etc)], which prevent excessive neointimal hyperplasia after stent implantation and lead to a reduction in the occurrence of ISR.

While initial DES clinical trials reported near undetectable rates of ISR following DES implantation in short-term
follow-up, both long-term follow-up as well as "real-world" applications of DES in complex lesions have determined that the incidence of DES-ISR (‘DES failure’) is about 5%–10% (Table 2).[6–15]

3 Pathophysiology

Vascular injury sustained during PCI and stent implantation results in a complex inflammatory and reparative process. The acute vascular reaction is characterized by early deposition of platelets and fibrin and adhesion of circulating neutrophils and monocytes to the injured vessel surface. Over weeks, acute inflammatory cells are replaced by chronic inflammatory cells (macrophages and giant cells). In addition to this inflammatory response, platelet- and leukocyte-related growth factors drive further vascular smooth muscle cells (VSMCs) proliferation and migration from the media to the nascent neointima and subsequent extracellular matrix formation. Two weeks following stent implantation, a complete neointimal layer, composed of VSMCs and a proteoglycan-rich extracellular matrix, can be observed above stent struts. The extracellular matrix is then covered from the luminal side by endothelial cells.[1–3] In BMS-ISR, the neointimal layer consists predominantly of VSMC surrounded by smaller amounts of extracellular matrix and a diffuse pattern of ISR is typical.[2,3,16] Peak BMS-ISR is observed at 3–6 months and remains relatively stable beyond one year.[1,2]

DES implantation results in delayed vessel wall healing, characterised by the presence of chronic fibrin deposits,

Table 1. Mehran’s angiographic classification of ISR.

| Type of ISR | Characteristics | Occurrence |
|-------------|-----------------|------------|
| I-focal     | Length < 10 mm  | 42%        |
| IA          | The articulation or gap between stents |            |
| IB          | The proximal or distal margin |            |
| IC          | The body of the stent |            |
| ID          | Multifocal      |            |
| II-diffuse  | Length >10 mm, not exceeding the edges of the stent | 21%         |
| III-proliferative | Exceeding the edges of the stent | 30%         |
| IV-occlusive| Total occlusion with TIMI 0 | 7%          |

ISR: in-stent restenosis; TIMI: thrombolysis in myocardial infarction.

Table 2. Comparisons of BMS vs. DES trials in de novo lesions.

| Trial         | No. of patients | Treatment | Follow-up          | The most important results                        |
|---------------|-----------------|-----------|--------------------|---------------------------------------------------|
| RAVEL[6,7]    | 238             | SES vs. BMS | 6 month angio       | Binary restenosis: 0% vs. 26.6%; TLR: 0% vs. 23.7%; MACE: 5.8% vs. 28.8%; P < 0.001 |
|               |                 |           | 12 month clinical  |                                                   |
|               |                 |           | 5 year clinical    |                                                   |
| SIRIUS[8,9]   | 322             | SES vs. BMS | 8 month angio       | Binary restenosis: 3.2% vs. 35.4%; P < 0.001 TLR: 4.9% vs. 20.2%; P < 0.001 MACE: 8.3% vs. 32.2%; P < 0.001 |
|               |                 |           | 12 month clinical  |                                                   |
|               |                 |           | 5 year clinical    |                                                   |
| TAXUS IV[10,11]| 1274           | PES vs. BMS | 9 month angio and clinical | Binary restenosis: 5.5% vs. 24.4%; P < 0.001 TLR: 9.1% vs. 20.5%; P = 0.001 MACE: 8.5% vs. 15%; P < 0.001 |
|               |                 |           | 5 year clinical    |                                                   |
| SPIRIT I[12,13]| 56             | EES vs. BMS | 6 month angio and clinical | Binary restenosis: 0% vs. 25.9%; P < 0.05 TLR: 3.8% vs. 21.4% MACE: 7.7% vs. 21.4% |
|               |                 |           | 5 year clinical    |                                                   |
| ENDEAVOR II   | 1197            | ZES vs. BMS | 12 month angio and clinical | Binary restenosis: 9.4% vs. 33.5%; P < 0.001 TLR: 4.6% vs. 11.8%; P < 0.001 MACE: 7.9% vs. 15.1%; P < 0.001 |
|               |                 |           | 5 year clinical    |                                                   |

BMS: bare-metal stent; DES: drug-eluting stent; EES: everolimus-eluting stent; MACE: major adverse cardiac events; SES: sirolimus-eluting stent; TLR: target lesion revascularisation; PES: paclitaxel-eluting stent; ZES: zotarolimus- eluting stent.
incomplete neoendothelization and long inflammatory changes.\[^5\] While fibrin deposits are replaced early on by neointimal tissue after BMS implantation, resulting in complete neoendothelisation within 3–6 months, DES implantation is associated with persistent fibrin deposits, a chronic inflammatory process and incomplete neoendothelisation for up to 48 months, accompanied by an associated risk of late stent thrombosis. Late vascular response after DES implantation is influenced further by the biocompatibility of the individual components of the stent, particularly the polymeric coating, which serves as a carrier and permits the controlled release of the active substance. This coating may cause persistent chronic inflammatory response in the vascular wall, leading to delayed healing and neointimal formation. In some cases, a non-specific acute inflammatory response may switch into a specific hypersensitivity reaction to polymer through the activation of eosinophils and T-lymphocytes.\[^5\]

The stent polymer facilitates controlled elution of anti-proliferative agents over a variable period of time. Importantly, the durable polymer (DP) serves no function once drug elution has been completed and, consequently, it may be associated with inflammation, delayed healing, incomplete endothelialization or accelerating neatherosclerosis which may contribute to the risk of late device failure compared with BMS. Contrary, biodegradable polymers (BP) may facilitate stent healing, thus enhancing clinical safety. The common BPs with therapeutic uses include polyactic acid, poly (lactic-co-glycolic acid) and poly (D,L-lactide). However, according to a recently published meta-analysis the safety and efficacy of BP-DES was similar as that of second-generation DP-DES [cardiovascular (CV) death, myocardial infarction (MI), TVR or late stent thrombosis; \(P = \text{NS for both}\)].\[^17\]

Compared to BMS-ISR, DES-ISR appears later; its presence can be felt from 6–9 months with a further increase up to the second year after implantation. The neointimal tissue consists mainly of an extracellular matrix with a minimum of VSMCs and the focal character of ISR lesions is typical, especially for sirolimus eluting stents restenosis (SES-ISR)\[^[13,16]\]

4 Neoatherosclerosis

The neointimal layer on implanted stents may suffer from recurrent atherosclerotic changes, i.e., neatherosclerosis. It appears that one of the predominant mechanisms involved in this process might be an incomplete regeneration of the endothelium leading to excessive uptake of circulating lipids and accelerated development of atherosclerotic plaques in the nascent neointima. Intimal thickening, intracellular lipid deposition with thin fibro-atheroma cap or the presence of necrotic tissue have been detected using histopathological or optical coherence tomography (OCT) evaluations.\[^18\]

Nakazawa, et al.\[^18\] found in their histopathological autopsy study that neatherosclerosis as a result of persistent endothelial dysfunction and incomplete neoendothelisation occurs more frequently (31% versus 16%; \(P < 0.001\)) and earlier (median: 420 vs. 2160 days; \(P < 0.001\)) following DES than BMS implantation. Moreover, neatherosclerosis in DES shows unstable characteristics (Thin-Cap Fibroatheromas or plaque rupture) earlier (about two years) after implantation, whereas similar features in BMS occur relatively later (about six years). Independent predictors of neatherosclerosis included younger age, longer implant durations, sirolimus-eluting stent (SES) or paclitaxel-eluting stent (PES) implantation and underlying unstable plaques.\[^18\] It is believed that neatherosclerosis, along with the rupturing of the thin fibro-atheroma plaque, are among the predominant causes of late stent failure (i.e., delayed ISR and late or very late stent thrombosis) which could manifest as acute coronary syndromes.\[^18\]

5 ISR risk factors

BMS-ISR risk factors can be divided into patient-, lesion- or peri-procedural risk factors (Table 3).\[^[1,3,19]\] Kastrati, et al.\[^20\] found lesion and periprocedural characteristics as predictive factors for ISR. Complex lesions (B2/C), restenosis, vessel size < 3 mm, stented segment > 15 mm and particular types of BMS are associated with an occurrence of ISR. The strongest risk factor seems to be a small vessel size, with a 79% increase in the risk for a vessel of 2.7 mm versus a vessel of 3.4 mm in diameter. Differences in the incidence of ISR between different types of BMS may vary between 20% and 50%,\[^[3,20]\] with significantly higher incidence in stents with thick struts compared to the newer stents with a thinner strut.\[^[21,22]\]

Table 3.  ISR risk factors.

| Patient’s factors | Lesion’s factors | Peri-procedural risk factors |
|-------------------|-----------------|----------------------------|
| Diabetes mellitus | Complex B2/C lesions | Sub-optimal apposition |
| Renal insufficiency | Long lesions > 20 mm | Under-expansion of the stent |
| Artery diameter < 3 mm | | Post-PCI MLD < 3 mm |
| Acute coronary syndromes | Chronic closures | Implantation of multiple |
| Ostial lesions | Stents | |
| Bifurcation lesions | Stent fractures | |
| Lesions in venous bypass | Type of stent | |
| recurrent restenosis | | |

ISR: in-stent restenosis; MLD: minimal lumen diameter; PCI: percutaneous coronary angioplasty.
The most important ISR risk factors seem to be diabetes mellitus, the length of the lesion and small vessel diameter. In a multivariate regression analysis, the main BMS-ISR risk factors are diabetes mellitus (OR: 1.86), implantation of multiple stents (OR: 1.81) and a post-procedural minimum lumen diameter < 3 mm (OR: 1.81). Diabetes itself increases the risk of BMS-ISR by 30%.[23–25] Similarly, the risk of DES-ISR is increased in diabetic patients when compared to those without diabetes.[1,26] The length of the lesion and vessel diameter pose other ISR risk factors independent of the presence of diabetes,[1,23,26] i.e., an implanted stent length > 35 mm is associated with almost double the ISR risk compared to < 20 mm stents.[1,27]

The major risk factors for recurrent ISR are diabetes mellitus, previous ISR and type according to Mehran’s classification (with an increase from I to IV).[3,4]

6  Biochemical and genetic risk factors

In addition to these known ISR risk factors, more biochemical or genetic factors are searched for that might contribute to the development of ISR. Mainly higher plasma levels of matrix metalloproteinases (MMPs), the proteolytic enzymes that degrade the extracellular matrix (ECM) and facilitate the proliferation and migration of endothelial and VSMCs, seem to be associated with a higher risk of in-stent restenosis.[28–30]

Many genome-wide association studies have observed single-nucleotide polymorphisms (SNPs) in individual genes, which could affect the occurrence of ISR, albeit with only a limited reach to clinical practice. One relatively large study was the GENetic DEterminants of Restenosis (GENDER) project, which examined 3100 patients with over 300 ISR cases after BMS implantation.[31] The association between some SNPs in AGTR, GPX1, KAT2B, MMP12, FGB and VDR genes and an increased risk of ISR was found.[32]

7  Diagnostics

7.1  Selective coronarography (SCG)

SCG is the standard diagnostic tool for the assessment of restenosis. Restenosis is arbitrarily defined as the repeated narrowing of the vessel lumen diameter with a cut-off value of ≥ 50%, known as “binary restenosis”.[3] However, neointimal hyperplasia, leading to re-narrowing of the lumen, represents a continuous process. Therefore, continuous variables are used to evaluate restenosis: the minimal lumen diameter (MLD), the percentage of diameter stenosis (DS%) and/or late lumen loss (LLL), representing the difference between post-procedural MLD and MLD at control coronary angiography. The use of these so-called “angiographic surrogate end-points” helps reduce the required cohort size while maintaining adequate statistical force.[33,34] A correlation, especially between LLL and DS%, and the incidence of angiographic and clinical restenosis, is proven.[33,34] Mauri, et al.[35] found a correlation between the LLL and the incidence of binary restenosis; LLL from 0.2 to 0.4 mm was associated with a 3.1% incidence of binary restenosis, as opposed to LLL of 0.4 to 0.6 mm, where the occurrence of ISRs increased to 6.4%. Similarly, Pocock, et al.[33] showed that LLL and DS% are able to predict with high accuracy the subsequent (TLR) after BMS/DES implantation (correlation coefficient about 0.90), wherein the predictive value of DS% does not depend on the artery’s diameter.

7.2  Intravascular ultrasound (IVUS)

IVUS allows for a detailed display of the stented segment during an assessment of the cross-section of individual vessel wall layers. It is able to exclude possible mechanical causes of ISR (under-expansion, stent fracture, etc.) and provide detailed information on the extent of neointimal hyperplasia.[36] Although stent implantation under IVUS control is not routinely recommended, one of the IVUS risk factors of angiographic and clinical restenosis is the resulting minimal lumen area of the stented segment (minimal stent area, MSA). MSA increases by 1 mm² are associated with a 20% decrease in BMS-ISR.[3,37] Post-procedural MSA > 5 mm² with SES and 6.5 mm² with BMS is a predictor of a satisfactory minimal lumen area (> 4 mm²) in the follow-up.[5,37,38]

7.3  Optical coherence tomography

OCT uses beam deflection with a frequency near to infrared light. This way, it achieves a significantly higher resolution compared to IVUS and allows for a more detailed assessment of stented segment.[3,5] Gonzalo, et al.[39] differentiate restenotic tissues according to their OCT images into the following subgroups: homogeneous, heterogeneous and stratified (layered) as well as low and high backscatter, whilst they also assess micro-vascularisation, lumen shape and the presence of intraluminal tissue. Diffuse ISR is characterised by a layered structure of neointimal tissue with high scattering, while focal lesions contain heterogeneous, low-scatter tissue.

7.4  Multi-slice CT (MS-CT) coronaryography

64- and more-slice MS-CT have been shown to permit the detection of coronary artery stenoses in the native coronary arteries with sensitivities and specificities up to 99%, but the visualization of the lumen within coronary artery
stents by MS-CT is more challenging.[40] A major issue with assessment of metallic stents involves “metal-blooming” artifact (blooming of stent struts) such that stents appear larger than they actually are or “beam-hardening” artifacts resulting in artificial luminal narrowing and decreased intraluminal attenuation values.[41,42] These artifacts are more significant in stents < 3.0 mm in diameter.[41,42] A method to determine coronary in-stent restenosis was based mainly on contrast attenuation inside the stent lumen. In-stent restenosis was considered if the vessel distal to the stent was not visualized (occlusion) or massive low-density area (or filling defects) inside the stent lumen was detected visually when compared with the reference vessel.[43] In meta-analyses, the sensitivity and specificity of MS-CT in detection of ISR achieved 90% and 91%, with positive and negative predictive value of 68% and 98%, respectively.[44,45]

8 Clinical presentation of ISR

Since ISR is based on gradually increasing neointimal hyperplasia, in-stent restenosis used to be considered a relatively benign process leading to recurrent exertional angina. However, there is evidence that 30%–60% of ISR can manifest as acute coronary syndromes, mostly as unstable angina pectoris or non-ST elevation acute myocardial infarction (UAP/NSTEMI).[3,5]

In the clinical database APPROACH, ISR manifested in 52.2% of cases as UAP/NSTEMI, in 18.5% as STEMI and only in 25.3% as stable AP.[46] It is believed that ISR manifestation as an acute coronary syndrome could be caused by neatherosclerosis and thin fibro-atheroma plaque rupture; this condition as well as delayed neointimalisation may cause late and very late DES stent thrombosis. The cause of stent occlusions may not be completely clear in the angiographic image. The behaviour of the lesion during the procedure (thromboaspiration, residual restenosis, etc) and imaging using IVUS or OCT may be helpful in differentiation between occluding neointimal hyperplasia and thrombotic occlusions due to neo-atherosclerotic changes or incomplete stent struts endothelialisation.[3,5]

The Mehran’s morphological character of ISR is a predictor of clinical events, with the necessity of repeated TVR between groups I-IV in 19%, 35%, 50% and 83% of cases, respectively (P < 0.001).[3,4]

9 Treatment of ISR

9.1 Bare-metal stent restenosis (BMS)

Repeated POBA or BMS implantation was associated with a high (nearly 40%) recurrence of binary restenosis,[47] cutting balloon dilatation did not reveal any significant benefit[48] and rotational atherectomy even led to outcomes inferior to POBA.[49] Brachytherapy has also been abandoned.

Current treatment for in-stent restenosis is based on DES. A drug released locally from the stent prevents new neointimal hyperplasia.[1,19] This treatment was established in the SISR and TAXUS V ISR trials, which compared the implantation of DES to relatively complicated brachytherapy.

In the SISR trial, the use of SES led to a significantly better angiographic outcomes and a trend to lower occurrence of repeated binary restenosis.[50]

The TAXUS V ISR trial found a significant decrease in TVR, repeated binary restenosis rate and also better clinical outcomes [major adverse cardiac events (MACE): CV death, MI or TVR] with the use of PES.[51]

The ISAR-DESIRE and RIBS II trials compared BMS-ISR treatment with DES implantation versus POBA. In the ISAR-DESIRE trial, implantation of SES or PES led to a significant decrease in repeated binary restenosis and TVR compared to POBA, whereas the direct comparison of both types of DES revealed a trend toward better outcomes in favor of SES.[52] Similarly, the RIBS II study revealed a significant decrease in restenosis and TVR after SES implantation.[53]

In contrast to DES, DEB catheters allow short-term passage of the active substance into the vascular wall, preventing hyperproliferation of VSMCs. Due to the short duration of the effect, DEB do not affect endothelial progenitor cells and stent neoendothelialization so much.[54–56]

Paclitaxel is used in the clinical practice as an effective antiproliferative agent in the case of DEB. Clinical data on the use of zotarolimus are also available.[57] Paclitaxel is highly lipophilic and rapidly penetrates into the tissues. Its concentrations used have stabilized at 3 μg/mm².[55,56]

The main factor influencing the efficacy of paclitaxel-eluting balloon catheters (PEB) is the method of paclitaxel binding on the surface of the balloon catheter. Paclitaxel can be freely applied directly to the roughened surface of the balloon catheter (first generation DIO®; Eurocor, Bonn, Germany) or is bound through the carrier, which affects its solubility and penetration through the vessel wall. In the original concept of Scheller, et al.,[55] paclitaxel was bound via iopromide, a hydrophilic contrast agent, which increased its solubility and penetration of the vascular wall (Paccocath). This method of preparation is used in modified form in PEB Sequent® Please (B.Braun, Melsulgen, Germany). In preclinical studies, iopromide-coated PEB showed
a significantly better angiographic outcomes than PEB without coating. In contrast, uncoated PEB failed to demonstrate any benefit compared to POBA.[58]

Many other PEBs are currently used in clinical practice: DION® II (shellac-coated; Eurocor, Bonn, Germany), IN.PACT Falcon [urea-coated; Medtronic, Minneapolis, USA], Pantera™ Lux (BTMC-coated (butyryl-tri-hexyl citrate); Biotronik, Berlin, Germany) and others.

The use of PEB in the treatment of ISR brings some benefits: compared to DES, PEBs allow homogeneous distribution of anti-proliferative treatment into the vessel wall with rapid achievement of an effective concentration; absence of polymers reduces chronic inflammatory response and the risk of subsequent late thrombosis; faster neointimalization allows shorter dual antiplatelet therapy and there is no risk of the occlusion of side branches with another layer of metallic struts.[59]

The efficacy of treatment with BMS-ISR using iopromide-coated PEB was demonstrated in comparison with PES. The Paccocath I and II trials demonstrated significantly better angiographic (lower LLL and repeated binary restenosis) and clinical outcomes (MACE) in the PEB groups compared to POBA.[60,61] Similarly, the PEPCAD II trial compared the treatment effect of PEB versus PES, showing significantly less 6-month LLL in the PEB group with a trend toward reducing the incidence of binary restenosis and 12-month MACE.[62]

The second generation DES releasing derivatives of sirolimus (everolimus, etc.) has higher efficacy and safety in the treatment of de novo lesions.[63] However, the Xience V US registry revealed significantly more target vessel failure (TVF; CV death, MI or TVR) after everolimus-eluting stent (EES) implantation in patients with ISR compared to those with non-ISR lesions.[64]

In several registries and observational trials, EES have been demonstrated to have at least the same angiographic and clinical outcomes in the treatment of BMS ISR as the first generation DES (PES/SES).[65,66]

In the recently published RIBS V trial, patients with BMS ISR were treated with PEB or EES (cobalt-chrome metallic platform). EES group had significantly higher 9-month MLD and lower DS%, however, there were not found any significant difference in LLL, repeated binary restenosis or TVR.[67]

Contrary to RIBS V, our TIS trial comparing iopromide-coated PEB and EES with a platinum-chromium metallic platform in the treatment of BMS-ISR demonstrated significantly lower 12-month LLL in the PEB group. The between-group differences in the incidence of repeated binary restenosis and 12-month MACE were also not significant.[68]

### 9.2 Restenosis in DES

In comparison with BMS-ISR, the treatment of DES-ISR is associated with worse long-term outcomes.[19,69] There is no clear consensus on whether the use of a different DES (hetero-DES) or a DES with a similar active substance (homo-DES) would be more beneficial.[19] The ISAR-DESIRE 2 trial found no angiographic or clinical differences in the treatment of SES-ISR using another SES or switching to PES.[70]

The prospective RIBS III registry compared the recommended strategy (hetero-DES, 75% of patients) to the control group (homo-DES, POBA, BMS). The hetero-DES group achieved a significantly better angiographic (higher MLD and fewer repeated binary restenosis) and clinical outcomes (MACE) compared to the disparate control group; whereas the direct comparison of hetero-DES and homo-DES subgroups revealed better outcomes in favor of hetero-DES.[71]

Similarly, the usage of PEB in the DES-ISR treatment was studied. The PEPCAD-DES trial compared the treatment of SES/PES-ISR using iopromide-coated PEB with POBA, and the use of PEB was associated with significantly better angiographic (lower LLL and repeated binary restenosis) and clinical end-points (MACE + stent thrombosis).[72]

In the PEPCAD ISR China trial, iopromide-coated PEB proved to be at least as effective as PES in the treatment of DES-ISR.[73] Habara, et al.[74] demonstrated better angiographic (lower LLL and repeated binary restenosis) and clinical outcomes (TVF) in patients with BMS/DES-ISR treated with iopromide-coated PEB compared to POBA. In the PEB group, significantly better results were achieved in the case of BMS-ISR compared to DES-ISR.

In the ISAR-DESIRE III study, the use of PEB was non-inferior to PES and either PEB or PES were superior to POBA alone in the treatment of SES-ISR, regarding to the primary angiographic end-point (follow-up residual %DS).[75] In the SeQuent Please World Wide Registry, PEB has been used predominantly for the treatment of ISR. Better 9-month clinical outcomes (TLR and MACE) were reported in patients with BMS-DES-ISR.[76]

In the Valentine prospective study, patients with BMS/DES-ISR were treated with shellac-coated PEB; after 6 to 9 months, the overall incidence of TVR and MACE achieved 8.6% and 11.1%. In a sub-analysis of patients treated for DES-ISR, a significantly better clinical outcomes (MACE
and TVR) was recorded in patients with PES-ISR compared to patients with SES-ISR.[77,78]

Naganuma, et al.[79] did not find any significant clinical difference (TVR and MACE) between urea-coated PEB and EES groups in the treatment of bifurcation BMS/DES-ISR.

9.3 New DES and different PEBs

New DES composed of biodegradable polymers, polymer free or containing novel antiproliferative drugs (e.g., zotarolimus, biolimus) promise better biocompatibility. They have been tested mostly in the treatment of de-novo lesions.[17,80] However, the randomised comparisons of biodegradable and durable polymer DES in the treatment of ISR are not available.

A recently published RESTENT-ISR study, comparing EES and zotarolimus-eluting stents (ZES) used for DES-ISR treatment, did not find any significant difference between both groups.[81]

The efficacy of individual PEBs is not identical, as it is markedly influenced by the applied coating. Nijhoff, et al.[82] found a significantly better angiographic, fractional flow reserve and OCT outcomes in the urea-coated PEB compared to shellac-coated PEB used for treatment of BMS/DES-ISR; however, only a trend towards lower LTR was observed.

In our registry, comparing different PEBs in the treatment of BMS-ISR, a seal-wing PEB was associated with significantly worse angiographic (higher MLD, lower LLL and repeated binary restenosis) and clinical outcomes (TVR and MACE) compared to iopromide-coated PEB.[83]

Only in the Düsseldorf DCB registry, patients treated for ISR, using BTHC-coated PEB, showed significantly better clinical outcomes compared to iopromide-coated PEB.[84]

In summary, both DES and DEB represent effective treatment of ISR. In comparison with BMS-ISR, DES-ISR treatment is associated with worse long-term outcomes. Among different PEBs, the best results are achieved with iopromide-coated ones. Results of the most important ISR trials are listed in Table 4.

9.4 Bioresorbable vascular scaffold restenosis (ScR)

One of the options employed to avoid the implantation of multiple metallic layers of stents into ISR (so called “onion skin”) could be the use of bioresorbable vascular scaffolds (BVS), which, compared with DEB, are able to achieve greater acute gain, prevent restenotic tissue prolapse and cover any edge dissection.

Jamshidi, et al.[85] proved the 100% peri-procedural success rate of everolimus-eluting BVS implantation in ISR lesions (96% in DES-ISR), which was associated with 12.2% repeated TVR at the 12-month follow-up.

In an Italian registry involving 127 patients with BMS/DES-ISR treated with BVS, 12-month target lesion failure (TLF) was 9.1% (6.4% in BMS-ISR and 10.9% in DES-ISR). Repeated TLR due to recurrence of restenosis in BVS (scaffold restenosis; ScR) was necessary in 6.3% of cases.[86]

In most studies with everolimus-BVS used in the treatment of de-novo lesions, the primary endpoint was TLF and the incidence of scaffold restenosis was not specified; however, the main issue of BVS seems to be a late scaffold thrombosis.[87] In the GHOST-EU registry, 6-month TLF was 4.4%, 82% of which (3.6% of cases in total) arising due to ScR.[88] The optimal treatment of ScR is unknown. In this registry, ScR was treated using PEB (in 43% of cases), DES (36%), POBA with NC post-dilatation (14%), and on one occasion a further BVS was implanted (7%).[88]

10 Clinical implications

Despite the risk of ISR, revascularization may reduce the absolute and relative risk of cardiac death more than medical therapy in patients with moderate-large amounts of stress induced myocardial ischemia. The degree of stress-induced ischemia and left ventricle ejection fraction (LVEF) predict the effect of revascularization on outcomes in patients with coronary artery disease. In patients with post-stress LVEF ≤ 45%, the survival benefit of revascularization was seen even in the absence of stress-induced ischemia. Contrary, in patients with post-stress LVEF > 45%, the survival benefit was depended on the presence of stress-induced ischemia.[89]

Despite the higher initial costs, the cost-effectiveness of the second generation DES implantations have been proved in recent meta analyses. The cost-reduction in the long term was primarily due to avoidance of secondary revascularisations and absence of myocardial infarction.[90]

11 Conclusions

Although the widespread usage of DES has reduced the incidence of ISR, this issue remains currently one of the main limitations of coronary interventions. Evidence resulting from controlled clinical trials suggests that DES and DEB provide the best angiographic and clinical outcomes in the treatment of ISR. However, new eluting balloons or stents (new antiproliferative drugs, biodegradable polymers or polymer-free etc) are rapidly evolving. Further studies are required to identify their potential benefit in the treatment of ISR.
Table 4. Summary of the most important trials of DES/DEB treatment for BMS/DES-ISR.

| Trial (year) | N  | Treatment | ISR type | Follow-up | The most important results |
|-------------|----|-----------|----------|-----------|--------------------------|
| RIBS (2003)  | 450 | POBA vs. BMS | BMS-ISR  | 6-month angio | Binary restenosis: 39% vs. 38%; P = NS |
|             |     |            |          | 12-month clinical | MLD: 2.25 ± 0.5 vs. 2.77 ± 0.4 mm; P = 0.001 |
| RESCUT (2004) | 428 | Cutting balloon vs. POBA | BMS-ISR | 7-month angio and clinical | Binary restenosis: 29.8% vs. 31.4%; P = 0.82 |
| ARTIST II (2002) | 298 | Rotablation vs. POBA | BMS-ISR | 6-month angio and clinical | TVF: 16.4% vs. 15.4%; P = 0.79 |
| SISR (2006)  | 384 | SES vs. Brachytherapy (β+γ radiation) | BMS-ISR | 6-month angio and clinical | LLL: 0.91 ± 0.57 vs. 0.67 ± 0.53 mm; P = 0.0015 |
|             |     |            |          | 6 and 9-month clinical | Binary restenosis: 64.8% vs. 51.2%; P = 0.039 |
| TAXUS V ISR (2006) | 396 | PES vs. Brachytherapy (β radiation) | BMS-ISR | 9-month angio and clinical | Ischemia-driven TVR: 10.5% vs. 17.5%; P = 0.046 |
| ISAR-DESIRE (2005) | 300 | DES (SES + PES) vs. POBA | BMS-ISR | 6-month angio and clinical | Binary restenosis: 14.3% (SES) and 21.7% (PES); P = 0.001 |
|             |     |            |          | 9-month clinical | TVR: 8.0% (SES) and 19.0% (PES); P < 0.004 |
| RIBS II (2006) | 150 | SES vs. POBA | BMS-ISR | 9-month angio and clinical | MACE: 23% vs. 35%; P = 0.046 |
|             |     |            |          | 12-month clinical | Binary restenosis: 11% vs. 39%; P < 0.001 |
| Paccoath I and II (2008) [49,50] | 108 | Iopromide-coated PEB vs. PES | BMS-ISR | 6-month angio and clinical | LLL: 0.11 ± 0.45 mm vs. 0.81 ± 0.79 mm; P < 0.001 |
| PEPCAD II (2009) | 131 | Iopromide-coated PEB vs. PES | BMS-ISR | 6-month angio and clinical | Binary restenosis: 6% vs. 51%; P < 0.001 |
|             |     |            |          | 12-month clinical | MACE: 11% vs. 46%; P = 0.001 |
| RIBS V (2014) | 189 | Iopromide-coated PEB vs. EES (Co/Cr) | BMS-ISR | 9-month angio and clinical | MLD: 2.01 ± 0.6 mm vs. 2.36 ± 0.6 mm; P < 0.001 |
|             |     |            |          | 12-month clinical | %DS: 25 ± 20% vs. 13 ± 17%; P < 0.001 |
| TIS (2016)  | 136 | Iopromide-coated PEB vs. EES (P/Cr) | BMS-ISR | 12-month angio and clinical | LLL: 0.09 ± 0.44 mm vs. 0.44 ± 0.73 mm; P = 0.0004 |
| ISAR-DESIRE II (2010) | 450 | SES vs. Iopromide-coated PES | SES-ISR | 6-month angio and clinical | Binary restenosis: 19.6% vs. 26.6%; P = 0.09 |
| RIBS III (2012) registry[27] | 363 | Hetero-DES vs. Control (homo-DES, POBA, BMS) | DES-ISR | 9-month angio and clinical | TLR: 16.6% vs. 14.6%; P = 0.52 |
| PEPCAD-DES (2012) | 110 | Iopromide-coated PEB vs. POBA | DES-ISR | 6-month angio and clinical | LLL: 0.43 ± 0.61 vs. 1.03 ± 0.77 mm; P < 0.001 |
| PEPCAD-ISR[28] | 220 | Iopromide-coated PEB vs. PES | DES-ISR | 9-month angio and clinical | Binary restenosis: 58.1% vs. 17.2%; P < 0.001 |
|             |     |            |          | 12-month clinical | MACE + stent thrombosis: 50.0% vs. 16.7%; P < 0.001 |
| Habara et al. (2013)[24] | 208 | Iopromide-coated PEB vs. POBA | BMS/DES-ISR | 6-month angio and clinical | LLL: 0.11 ± 0.33 vs. 0.40 ± 0.50 mm; P < 0.001 |
| ISAR-DESIRE III (2013)[29] | 402 | PES vs. Iopromide-coated PEB vs. POBA | SES-ISR | 6-month angio and clinical | %DS: PEB vs. SES: 38 ± 21.5% vs. 37.4 ± 21.8%; P_{superiority} = 0.007 |

Note: TLR: Target lesion revascularization; TVF: target vessel failure; TVR: target vessel revascularization; MACE: major adverse cardiac events; LLL: luminal loss; MLD: minimal lumen diameter; %DS: percent diameter stenosis; MACE: 12-month clinical follow-up; PEB: Proliferative Endothelial Balloon; POBA: P-bend overlapping balloon angioplasty; DES: drug-eluting stent; BMS: bare metal stent; ISR: in-stent restenosis; P = non-inferiority = 0.007; P_{superiority} = 0.0001 for both.
Table 4. Cont.

| Trial (year) | N   | Treatment                  | ISR type | Follow-up                        | The most important results                  |
|-------------|-----|----------------------------|----------|----------------------------------|---------------------------------------------|
| Düsseldorf  | 571 | BTHC-coated PEB            | DES/ISR  | in-hospital and clinical         | Longer EFS (HR: 0.65; 95%CI: 0.43–0.98; P = 0.405) |
| DCB registry (2017) | 181 | Iopromide-coated PEB       | DES/ISR  | 9-month clinical                 | MACE: 15.8% vs. 22.6%; P = 0.276            |
| World Wide Registry (2012) | 1523 | Iopromide-coated PEB       | DES-ISR  | 9-month clinical                 | LLL: 0.40 ± 0.56 vs. 0.45 ± 0.61 mm; P = 0.57 |
| World Wide Registry (2011) | 250 | Shellac-coated PEB         | BMS/DES-ISR | 6 to 9-month clinical            | PES- vs. SES-ISR: MACE: 0% vs. 23.8%; P = 0.002 |
| Naganuma et al. (2014) registry | 158 | Urea-coated PEB vs. EES    | BMS/DES-ISR | 2-year clinical                  | TVR: 0% vs. 16.7%; P = 0.015                |
| RESTENT-ISR (2016) | 304 | EES vs. ZES                | DES-ISR  | 9-month angio 3-year clinical    | TVR: 23.7% vs. 21.8%; P = 0.884             |
| Nijhoff, et al. registry | 45  | Urea-coated vs. shellac-coated PEB DES-ISR | 6-month angio | LLL: -0.03 ± 0.43 vs. 0.36 ± 0.48 mm; P = 0.014 |
| Pleva, et al. (2017) registry | 136 | Seal-wing PEB vs. iopromide-coated PEB DES-ISR | 12-month angio and clinical | MLD: 1.68 vs. 2.13 mm; P = 0.0006 |

BMS: bare-metal stent; BTHC: butyryl-tri-hexyl citrate; Co/Cr: cobalt-chromium; DEB: drug-eluting balloon catheter; DES: drug-eluting stent; EES: everolimus-eluting stent; EFS: event-free survival; FFR: fractional flow reserve; HR: hazard rate; ISR: in-stent restenosis; LLL: late lumen loss; MACE: major adverse cardiac events; MLD: minimal lumen diameter; PEB: paclitaxel-eluting balloon catheter; SES: sirolimus-eluting stent; %DS: percent diameter stenosis; POBA: plane old balloon angioplasty; PtCr: platinum-chromium; SES: sirolimus-eluting stent; TVR: target vessel failure; TVR/TLR: target vessel/lesion revascularisation; vol%IH: volume percent intimal hyperplasia; ZES: zotarolimus-eluting stent.

Acknowledgments

This article was supported by Ministry of Health, Czech Republic-conceptual development of research organizations—FNOs/2015.

References

1. Kim MS, Dean LS. In-stent restenosis. Cardiovasc Ther 2011; 29: 190–198.
2. Scott NA. Restenosis following implantation of bare metal coronary stents: Pathophysiology and pathways involved in the vascular response to injury. Adv Drug Deliv Rev 2006; 58: 358–376.
3. Byrne RA, Joner M, Massberg S, et al. Restenosis in bare metal and drug-eluting stents. In Coronary stenosis, imaging, structure and physiology, 1st Edition; Escaned J, Serruys PW, Eds.; Europa Edition: Toulouse, France, 2010; 475–496.
4. Mehran R, Dangas G, Abizaid AS, et al. Angiographic patterns of in-stent restenosis classification and implications for long-term outcome. Circulation 1999; 100: 1872–1878.
5. Farooq V, Räber L, Gogas BD, et al. In-stent restenosis. In Percutaneous interventional cardiovascular medicine, the PCR-EAPCI textbook, 1st Edition; Eeckhout E, Serruys PW, Wijns W, et al., Eds.; Europa Edition: Toulouse, France, 2012; 785–826.
6. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346: 1773–1780.
7. Morice MC, Serruys PW, Barragan P, et al. Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial. J Am Coll Cardiol 2007; 50: 1299–1304.
8. Holmes DR, MB, Moses JW, et al. Analysis of 1-year clinical outcomes in the SIRIUS trial a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation 2004; 109: 634–640.
9. Weisz G, Leon MB, Holmes DR, et al. Five-year follow-up
after sirolimus-eluting stent implantation results of the SIRIUS (Sirolimus-Eluting Stent in De-Novo Native Coronary Lesions) Trial. J Am Coll Cardiol 2009; 53: 1488–1497.

21 Stone GW, Ellis SG, Cox DA, et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent the TAXUS-IV trial. Circulation 2004; 109: 1942–1947.

22 Ellis SG, Stone GW, Cox DA, et al. Long-term safety and efficacy with paclitaxel-eluting stents 5-year final results of the TAXUS IV clinical trial. J Am Coll Cardiol Intv 2009; 2: 1248–1259.

23 Serruys PW, Ong ATL, Piek JJ, et al. A randomized comparison of a durable polymer everolimus-eluting stent with a bare metal coronary stent: the SPIRIT first trial. EuroInterv 2005; 1: 58–65.

24 Beijk MA, Neumann FJ, Wiemer M, et al. Two-year results of a durable polymer everolimus-eluting stent in de novo coronary artery stenosis (The SPIRIT FIRST Trial). EuroInterv 2010; 3: 206–212.

25 Fajadet J, Wijns W, Laarman GJ, et al. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation 2006; 114: 798–806.

26 Mauri L, Massaro JM, Jiang S, et al. Long-term clinical outcomes with zotarolimus-eluting versus bare-metal coronary stents. J Am Coll Cardiol Intv 2010; 3: 1240–1249.

27 Cosgrave J, Melzi G, Biondi-Zoccai GGL, et al. Drug-eluting stent restenosis the pattern predicts the outcome. J Am Coll Cardiol 2006; 47: 2399–2404.

28 El-Hayek G, Bangalore S, Casso Dominguez A, et al. Meta-analysis of randomized clinical trials comparing biodegradable polymer drug-eluting stent to second-generation durable polymer drug-eluting stents. JACC Cardiovasc Interv 2017; 10: 462–473.

29 Nakazawa G, Otsuka F, Nakano M, et al. The Pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. J Am Coll Cardiol 2011; 57: 1314–1322.

30 Alfonso F, Byrne RA, Rivero F, et al. Current treatment of in-stent restenosis. JACC 2014; 63: 2659–2673.

31 Kastrati A, Mehilli J, Dirschinger J, et al. Restenosis after coronary placement of various stent types. Am J Cardiol 2001; 87: 34–39.

32 Yoshitomi Y, Kojima S, Yano M, et al. Does stent design affect probability of restenosis? A randomized trial comparing multilink stents with GFX stents. Am Heart J 2001; 142: 445–451.

33 Pache J, Kastrati A, Mehilli J, et al. Intracoronary stenting and angiographic results: Strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial. J Am Coll Cardiol 2003; 41: 1283–1288.

34 Kastrati A, Schomig A, Elezi S, et al. Predictive factors of restenosis after coronary stent placement. J Am Coll Cardiol 1997; 30: 1428–1436.

35 Jukema JW, Verschuren JJ, Ahmed TA, et al. Restenosis after PCI. Part 1: pathophysiology and risk factors. Nat Rev Cardiol 2012; 9: 53–62.

36 Elezi S, Kastrati A, Pache J, et al. Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. J Am Coll Cardiol 1998; 32: 1866–1873.

37 Kastrati A, Dibra A, Mehilli J, et al. Predictive factors of restenosis after coronary implantation of sirolimus- or paclitaxel-eluting stents. Circulation 2006; 113: 2293–2300.

38 Kobayashi Y, De Gregorio J, Kobayashi N, et al. Stented segment length as an independent predictor of restenosis. J Am Coll Cardiol 1999; 34: 651–659.

39 Jones GT, Tarr GP, Phillips LV, et al. Active matrix metalloproteinases 3 and 9 are independently associated with coronary artery in-stent restenosis. Atherosclerosis 2009; 207: 603–607.

40 Tarr GP, Williams GT, Wilkins VHT, et al. Intra-individual changes of active matrix metalloproteinase-9 are associated with clinical in-stent restenosis of bare metal stents. Cardiovasc Res 2013; 124: 28–35.

41 Katsaros KM, Kastl SP, Zorn G, et al. Increased restenosis rate after implantation of drug-eluting stents in patients with elevated serum activity of matrix metalloproteinase-2 and -9. J Am Coll Cardiol Intv 2010; 3: 90–97.

42 Sampietro ML, Pons D, de Knijff P, et al. A genome wide association analysis in the GENDER study. Neth Heart J 2009; 17: 262–264.

43 Verschuren JJW, Trompet S, Postmus I, et al. Systematic testing of literature reported genetic variation associated with coronary restenosis: results of the GENDER Study. PLoS One 2012; 7: e42401.

44 Pocock SJ, Lansky AJ, Mehran R, et al. Angiographic surrogate end points in drug-eluting stent trials. JACC 2008; 51: 23–32.

45 Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials. A case for standardized definitions. Circulation 2007; 115: 2344–2351.

46 Mauri L, Orav EJ, Kuntz RE. Late loss in lumen diameter and binary restenosis for drug-eluting stent comparison. Circulation 2005; 111: 3435–3442.

47 Garcia-Garcia HM, Shen Z, Piazza M. Study of restenosis in drug eluting stents: new insights from greyscale intravascular ultrasound and virtual histology. EuroInterv 2009; 5(Suppl D): D84–D92.

48 Kasaoka S, Tobis JM, Akiyama T, et al. Angiographic and intravascular ultrasound predictors of in-stent restenosis. J Am Coll Cardiol 1998; 32: 1630-1635.

49 Sonoda S, Morino Y, Ako J, et al. Impact of final stent dimensions on long-term results following sirolimus-eluting stent implantation: serial intravascular ultrasound analysis from the SIRIUS trial. J Am Coll Cardiol 2004; 43: 1959–1963.

50 Gonzalez N, Serruys PW, Okamura T, et al. Optical coherence tomography patterns of stent restenosis. Am Heart J 2009; 158: 284–293.
artery stent restenosis by 64-slice multi-detector computed tomography. *Eur Heart J* 2006; 27: 2567–2572.

Andreini D, Pontone G, Mushtaq S, et al. Coronary in-stent restenosis: assessment with CT coronary angiography. *Radiology* 2012; 265: 410–417.

Mahnken AH. CT imaging of coronary stents: past, present, and future. *ISRN Cardiol* 2012; 2012: 139823.

Sun Z, Davidson R, Lin CHS. Multi-detector row CT angiography in the assessment of coronary in-stent restenosis: A systematic review. *Eur J Radiol* 2009; 69: 489–495.

Sun Z, Almutairi AMD. Diagnostic accuracy of 64 multislice CT angiography in the assessment of coronary in-stent restenosis: A meta-analysis. *Eur J Radiol* 2010; 73: 266–273.

Kumbhani DJ, Ingelmo CP, Schoenhagen P, et al. Meta-analysis of diagnostic efficacy of 64-slice computed tomography in the evaluation of coronary in-stent restenosis. *Am J Cardiol* 2009; 103: 1675–1681.

Bainey KR, Norris CM, Graham MM, et al. Clinical in-stent restenosis with bare metal stents: Is it truly a benign phenomenon? *Int J Cardiol* 2008; 128: 378–382.

Alfonso F, Zucco J, Cequier A et al. A randomized comparison of repeat stenting with balloon angioplasty in patients with in-stent restenosis. *J Am Coll Cardiol* 2003; 42: 796–805.

Albiero R, Silber S, Di Mario C, et al. Cutting balloon versus conventional balloon angioplasty for the treatment of in-stent restenosis: Results of the restenosis cutting balloon evaluation trial (RESCUT). *J Am Coll Cardiol* 2004; 43: 943–949.

vom Dahl J, Dietz U, Haager PK et al. Rotational atherectomy does not reduce recurrent in-stent restenosis results of the angioplasty versus rotational atherectomy for treatment of diffuse in-stent restenosis trial (ARTIST). *Circulation* 2002; 105: 583–588.

Holmes DR Jr, Teirstein P, Satller L, et al. Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the SISR randomized trial. *JAMA* 2006; 295: 1264–1273.

Stone GW, Ellis SG, O’Shaughnessy CD, et al. Paclitaxel-eluting stents vs. vascular brachytherapy for in-stent restenosis within bare-metal stents: The TAXUS V ISR Randomized Trial. *JAMA* 2006; 295: 1253–1263.

Kastrati A, Mehilli J, von Beckerath N, et al. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: A randomized controlled trial. *JAMA* 2005; 293: 165–171.

Alfonso F, Pérez-Vizcayno MJ, Hernandez R, et al. A Randomized comparison of sirolimus-eluting stent with balloon angioplasty in patients with in-stent restenosis results of the restenosis intrastent: balloon angioplasty versus elective sirolimus-eluting stenting (RIBS-II) trial. *J Am Coll Cardiol* 2006; 47: 2152–2160.

Belkacemi A, Agostoni P, Voskuil M, et al. Drug-eluting balloons in coronary artery disease—current and future perspectives. *J Interv Cardiol* 2011; 6: 157–160.

Scheller B, Speck U, Abramjuk C, et al. Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis. *Circulation* 2004; 110: 810–814.

Cortese B, Bertoletti A. Paclitaxel coated balloons for coronary artery interventions: A comprehensive review of preclinical and clinical data. *Int J Cardiol* 2012; 161: 4–12.

Cremers B, Toner JL, Schwartz LB, et al. Inhibition of neointimal hyperplasia with a novel zotarolimus coated balloon catheter. *Clin Res Cardiol* 2012; 101: 469–476.

Speck U, Scheller B, Abramjuk C, et al. Inhibition of restenosis in stented porcine coronary arteries: uptake of Paclitaxel from angiographic contrast media. *Invest Radiol* 2004; 39: 182–186.

Chin K. In-stent restenosis: the gold standard has changed. *EuroIntervention* 2011; 7: K43–K46.

Scheller B, Hehrlein C, Bocksch W, et al. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. *N Engl J Med* 2006; 355: 2113–2124.

Scheller B, Hehrlein C, Bocksch W, et al. Two year follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. *Clin Res Cardiol* 2008; 97: 773–781.

Unverdorben M, Vallbracht C, Cremers B, et al. Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis. *Circulation* 2009; 119: 2986–2994.

Alfonso F, Fernandez C. Second-generation drug-eluting stents. Moving the field forward. *J Am Coll Cardiol* 2011; 58: 26–29.

Lee MS, Yang T, Mahmud E, et al. Clinical outcomes in the percutaneous coronary intervention of in-stent restenosis with everolimus-eluting stents. *J Invasive Cardiol* 2014; 26: 420–426.

Almalla M, Schröder JW, Pross V, et al. Everolimus-eluting versus paclitaxel-eluting stents for treatment of bare metal stent restenosis. *Am J Cardiol* 2011; 108: 518–522.

Markovic S, Paliskyte R, Rotthauer W, et al. Everolimus-eluting stents compared with paclitaxel-eluting stents for treatment of coronary in-stent restenoses. *Cardiovasc Revasc Med* 2012; 13: 307–310.

Alfonso F, Pérez-Vizcayno MJ, Cárdenas A, et al. A randomized comparison of drug-eluting balloon versus everolimus-eluting stent in patients with bare-metal stent in-stent restenosis. *JACC* 2014; 63: 1378–1386.

Pleva L, Kukla P, Kusnierova P, et al. Comparison of the efficacy of paclitaxel-eluting balloon catheters and everolimus-eluting stents in the treatment of coronary in-stent restenosis. The treatment of in-stent restenosis study. *Circ Cardiovasc Interv* 2016; 9: e003316.

Latib A, Mussardo M, Ielasi A, et al. Long-term outcomes after the percutaneous treatment of drug-eluting stent restenosis. *J Am Coll Cardiol Intv* 2011; 4: 155–164.

Mehilli J, Byrne RA, Tiroch K, et al. Randomized trial of paclitaxel- versus sirolimus-eluting stents for treatment of coronary restenosis in sirolimus-eluting stents: the ISAR-
DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) study. *J Am Coll Cardiol* 2010; 55: 2710–2716.

71 Alfonso F, Pérez-Vizcayno MJ, Dutary J, *et al.* Implantation of a drug-eluting stent with a different drug (switch strategy) in patients with drug-eluting stent restenosis. Results from a prospective multicenter study (RIBS III [Restenosis Intra-Stent: Balloon Angioplasty Versus Drug-Eluting Stent]). *J Am Coll Cardiol Intv* 2012; 5: 728–737.

72 Ritter H, Brachmann J, Sinha AM, *et al.* A randomized, multicenter, single-blinded trial comparing paclitaxel-coated balloon angioplasty with plain balloon angioplasty in drug-eluting stent restenosis: the PEPCAD-DES study. *J Am Coll Cardiol* 2012; 59: 1377–1382.

73 Xu B, Gao R, Wang J, *et al.* A prospective, multicenter, randomized trial of paclitaxel-coated balloon versus paclitaxel-eluting stent for the treatment of drug-eluting stent in-stent restenosis: results from the PEPCAD China ISR trial. *J Am Coll Cardiol Intv* 2014; 7: 204–211.

74 Habara S, Ibawuchi M, Inoue N, *et al.* A multicenter randomized comparison of paclitaxel-coated balloon catheter with conventional balloon angioplasty in patients with bare-metal stent restenosis and drug-eluting stent restenosis. *Am Heart J* 2013; 166: 527–533.

75 Byrne RA, Neumann FJ, Mehilli J, *et al.* Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trial. *Lancet* 2013; 381: 461–467.

76 Wörhle J, Zadura M, Möbius-Winkler S, *et al.* SeQuent Please World Wide Registry: Clinical results of SeQuent please paclitaxel-coated balloon angioplasty in a large-scale, prospective registry study. *JACC* 2012; 60: 1733–1738.

77 Stella PR, Belkacemi A, Waksman R, *et al.* The Valentines Trial: results of the first one week worldwide multicentre enrollment trial, evaluating the real world usage of the second generation DIO R paclitaxel drug-eluting balloon for in-stent restenosis treatment. *EuroInterv* 2011; 7: 705–710.

78 Loh JP, Pieter R, Stella PR, *et al.* Paclitaxel-coated balloon for the treatment of drug-eluting stent restenosis: subanalysis results from the Valentines I trial. *Catheter and Cardiovasc Interv* 2014; 15: 23–28.

79 Naganuma T, Latib A, Costopoulos C, *et al.* Drug-eluting balloon versus second-generation drug-eluting stent for the treatment of restenotic lesions involving coronary bifurcations. *EuroInterv* 2016; 11: 989–995.

80 Kereiakes DJ, Meredith IT, Windecker S, *et al.* Efficacy and safety of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent: the EVOLVE II randomized trial. *Circ Cardiovasc Interv* 2015; 8: e002372.

81 Hong SJ, Ahn CM, Kim BK, *et al.* Prospective randomized comparison of clinical and angiographic outcomes between everolimus-eluting vs. zotarolimus-eluting stents for the treatment of coronary restenosis in drug-eluting stents: intravascular ultrasound volumetric analysis (RESTENT-ISR trial). *Eur Heart J* 2016; 37: 3409–3418.

82 Nijhoff F, Stella PR, Troost MS, *et al.* Comparative assessment of the antirestenotic efficacy of two paclitaxel drug-eluting balloons with different coatings in the treatment of in-stent restenosis. *Clin Res Cardiol* 2016; 105: 401–411.

83 Pleva L, Kukla P, Zapletalova J, *et al.* Efficacy of a seal-wing paclitaxel-eluting balloon catheters in the treatment of bare metal stent restenosis. *BMC Cardiovasc Disor* 2017; 17: 168.

84 Assadi-Schmidt A, Mohring A, Liebsch E, *et al.* SeQuent Please vs. Pantera Lux drug coated balloon angioplasty in real life: Results from the Düsseldorf DCB registry. *Int J Cardiol* 2017; 231: 68–72.

85 Jamshidi P, Nyffenegger T, Sabti Z, *et al.* A novel approach to treat in-stent restenosis: 6- and 12-month results using the everolimus-eluting biodegradable vascular scaffold. *EuroInterv* 2016; 11: 1479–1486.

86 Moscarella E, Ielasi A, Granata F, *et al.* Long-term clinical outcomes after biodegradable vascular scaffold implantation for the treatment of coronary in-stent restenosis a multicenter italian experience. *Circ Cardiovasc Interv* 2016; 9: e003148.

87 Capodanno D, Gori T, Neft H, *et al.* Percutaneous coronary intervention with everolimus-eluting biodegradable vascular scaffolds in routine clinical practice: Early and midterm outcomes from the european multicenter GHOST-EU registry. *EuroInterv* 2015; 10: 1144–1153.

88 Longo G, Granata F, Capodanno D, *et al.* Anatomical features and management of biodegradable vascular scaffolds failure: a case series from the GHOST registry. *Catheter and Cardiovasc Interv* 2015; 85: 1150–1161.

89 Petretta M, Acampa W, Daniele S, *et al.* Long-term survival benefit of coronary revascularization in patients undergoing stress myocardial perfusion imaging. *Circ J* 2016; 80: 485–493.

90 Baschet L, Bourguignon S, Marque S, *et al.* Cost-effectiveness of drug-eluting stents versus bare-metal stents in patients undergoing percutaneous coronary intervention. *Open Heart* 2016; e000445.